SDGR Schrodinger, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1490978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.8%
TTM net income YoY66.3%
TTM EPS YoY67.1%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR—
Margins
Gross margin58.5%
Operating margin-49.6%
Net margin-22.0%
FCF margin-43.4%
EBITDA margin-47.5%
Returns
ROE-19.0%
ROA-9.4%
ROIC (approx.)-108.6%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets50.7%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.90x
Accruals ratio8.4%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $255.87M | $207.54M |
| Cost of revenue | $113.25M | $75.46M |
| Gross profit | $142.61M | $132.08M |
| R&D expense | $173.14M | $201.78M |
| SG&A expense | $95.41M | $99.68M |
| Operating income | -$166.90M | -$209.30M |
| Pretax income | -$102.33M | -$185.71M |
| Income tax | $939,000 | $1.41M |
| Net income | -$103.27M | -$187.12M |
| EBITDA | -$160.87M | -$203.14M |
| EPS (basic) | -1.41 | -2.57 |
| EPS (diluted) | -1.41 | -2.57 |
| Weighted avg. shares (diluted) | 73.44M | 72.67M |
| Balance sheet | ||
| Cash & equivalents | $230.52M | $162.66M |
| Short-term investments | $164.95M | $204.80M |
| Receivables | $83.04M | $235.69M |
| Current assets | $519.26M | $634.99M |
| PP&E, net | $19.46M | $24.20M |
| Goodwill | $4.79M | $4.79M |
| Total assets | $726.16M | $823.23M |
| Current liabilities | $189.14M | $191.75M |
| Total liabilities | $362.11M | $401.78M |
| Shareholders' equity | $364.05M | $421.44M |
| Cash flow statement | ||
| Operating cash flow | $13.90M | -$157.37M |
| Capital expenditure | $1.44M | $7.31M |
| Free cash flow | $12.46M | -$164.68M |
| Investing cash flow | $57.90M | $148.84M |
| Financing cash flow | $2.93M | $10.12M |
| Depreciation & amortization | $6.02M | $6.16M |
| Stock-based compensation | $43.00M | $49.90M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.